Repros Therapeutics Inc (NASDAQ:RPRX)
During the Trading Day
| 16.50 |  +0.68 / +4.30% |
Data as of 4:00pm ET | Day’s Change |
During After-Hours Switch to standard view »
| 16.50 | +0.0033 / +0.02% |
Volume: 922.00 |
Latest RPRX News | Press Releases
| Repros to Conduct Phase IIb Trial - Analyst Blog May 23 / Zacks.com |
Today’s Trading
| Previous close | 15.82 |
| Today’s open | 15.83 |
| Day’s range | 15.73 - 16.87 |
| Volume | 358,039 |
| Average volume (3 months) | 688,160 |
| Market cap | $294.9M |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/24/2013
Growth & Valuation
| Earnings growth (last year) | -13.46% |
| Earnings growth (this year) | -13.35% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | 11.79 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| NAVBNavidea Biopharmaceu... | -0.06 | -2.40% |
| SNSSSunesis Pharmaceutic... | +0.04 | +0.72% |
| VICLVical Inc | -0.08 | -2.23% |
| ACRXAcelRx Pharmaceutica... | +0.41 | +5.50% |
Data as of 4:01pm ET, 05/24/2013
Financials
| Next reporting date | August 19, 2013 |
| EPS forecast (this quarter) | -$0.35 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$18.2M |
| Net profit margin | -- |
Profile
Sector Health Technology |
Industry Medical Specialties |
President, Chief Executive Officer & Director Joseph S. Podolski |
Secretary, Chief Financial & Accounting Officer Katherine A. Anderson, CPA |
Corporate headquarters The Woodlands, Texas |
Forecasts
